Medicare Enrolled
Dr. Steven Young, M.D.
Hematology & Oncology · Bridgewater, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Young from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Young?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Young
Dr. Steven Young is a hematology & oncology specialist in Bridgewater, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Young performed 65,718 Medicare services across 2,078 unique beneficiaries.
Between the years covered by Open Payments, Dr. Young received a total of $2,651 from 45 pharmaceutical and/or device companies across 109 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Young is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 18% volume in NJ
$2,651 industry payments
Medicare Practice Summary
Medicare Utilization ↗65,718
Medicare services
Top 18% in NJ for hematology & oncology
2,078
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,286 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
26,250 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 12,800 | $43 | $161 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
6,300 | $2 | $10 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
5,800 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 5,640 | $19 | $68 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
1,680 | $6 | $25 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,334 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
945 | $105 | $421 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
790 | $8 | $23 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
727 | $12 | $48 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
619 | $8 | $27 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
555 | $6 | $14 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
532 | $67 | $246 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
248 | $26 | $101 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
248 | $119 | $462 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
191 | $1 | $6 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
171 | $56 | $229 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
97 | $17 | $71 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
90 | $152 | $587 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
86 | $110 | $424 |
| Anticoagulant management for warfarin Management of anticoagulant therapy for a patient taking warfarin. This service involves monitoring and adjusting the medication regimen. |
80 | $10 | $38 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
75 | $1 | $3 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
63 | $60 | $226 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 61 | $342 | $1,453 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
59 | $13 | $55 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
52 | $26 | $99 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
48 | $70 | $299 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
42 | $145 | $545 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
39 | $100 | $372 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
34 | $87 | $398 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
24 | $138 | $591 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
19 | $4 | $13 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
19 | $234 | $914 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
41.2% high complexity
52.8% medium
6.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,651
Total received (2018-2024)
Avg $379/year across 7 years
Bottom 46% in NJ for hematology & oncology
45
Companies
109
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,317 (87.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$335 (12.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$782
2023
$783
2022
$359
2021
$11
2020
$105
2019
$97
2018
$515
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$167
Gilead Sciences, Inc.
$140
SOBI, INC
$34
Incyte Corporation
$33
PFIZER INC.
$32
Pharmacosmos Therapeutics Inc.
$25
Mirati Therapeutics, Inc.
$25
Daiichi Sankyo Inc.
$25
BeiGene USA, Inc.
$23
ARRAY BIOPHARMA INC
$22
Janssen Biotech, Inc.
$22
Stemline Therapeutics Inc.
$20
Merck Sharp & Dohme LLC
$20
TAIHO ONCOLOGY, INC.
$19
Novartis Pharmaceuticals Corporation
$18
AstraZeneca Pharmaceuticals LP
$18
Ipsen Biopharmaceuticals, Inc
$17
Genentech USA, Inc.
$17
Astellas Pharma US Inc
$17
Regeneron Healthcare Solutions, Inc.
$17
PUMA BIOTECHNOLOGY, INC.
$15
Octapharma USA, Inc.
$15
E.R. Squibb & Sons, L.L.C.
$14
Blueprint Medicines Corporation
$13
Lilly USA, LLC
$13
Top 3 companies account for 43.6% of 2024 payments
All-time payments by company (2018-2024) ›
Gilead Sciences, Inc.
$298
E.R. Squibb & Sons, L.L.C.
$239
Daiichi Sankyo Inc.
$203
Amgen Inc.
$186
GlaxoSmithKline, LLC.
$167
Epizyme, Inc.,
$125
Karyopharm Therapeutics Inc.
$125
Janssen Biotech, Inc.
$113
Blueprint Medicines Corporation
$107
Novartis Pharmaceuticals Corporation
$87
Genentech USA, Inc.
$70
Merck Sharp & Dohme Corporation
$69
AstraZeneca Pharmaceuticals LP
$63
PFIZER INC.
$52
Pharmacosmos Therapeutics Inc.
$49
Astellas Pharma US Inc
$49
Mirati Therapeutics, Inc.
$43
Merck Sharp & Dohme LLC
$38
Ipsen Biopharmaceuticals, Inc
$34
AbbVie Inc.
$34
SOBI, INC
$34
Incyte Corporation
$33
Bayer HealthCare Pharmaceuticals Inc.
$30
GENZYME CORPORATION
$29
EMD Serono, Inc.
$28
Teva Pharmaceuticals USA, Inc.
$26
Janssen Scientific Affairs, LLC
$26
BeiGene USA, Inc.
$23
ARRAY BIOPHARMA INC
$22
ADC Therapeutics America, Inc.
$21
Stemline Therapeutics Inc.
$20
TAIHO ONCOLOGY, INC.
$19
Regeneron Healthcare Solutions, Inc.
$17
Genmab U.S., Inc.
$17
Celgene Corporation
$17
PUMA BIOTECHNOLOGY, INC.
$15
Verastem, Inc.
$15
Octapharma USA, Inc.
$15
Janssen Pharmaceuticals, Inc
$14
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Clovis Oncology, Inc.
$14
Seattle Genetics, Inc.
$14
Lilly USA, LLC
$13
Kyowa Kirin, Inc.
$12
AbbVie, Inc.
$12
Top 3 companies account for 27.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Alecensa · Aliqopa · BENDEKA · BRUKINSA · Bavencio · Blincyto · CALQUENCE · COSELA · Columvi · Copiktra · DARZALEX · DOPTELET · ELIQUIS · ELREXFIO · ENHERTU · ERLEADA · Enhertu · Epkinly · FARESTON · GILOTRIF · IBRANCE · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KRAZATI · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · MONOFERRIC · Neulasta · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDIVO · Onivyde · Orserdu · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Rubraca · SIMPONI ARIA · SPRYCEL · TAGRISSO · TALVEY · TAZVERIK · TECENTRIQ · TEPMETKO · Trodelvy · VENCLEXTA · VOTRIENT · Venclexta · XARELTO · XPOVIO · XTANDI · Xtandi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
154
Per 100K population
44.5
County median income
$135,960
Nearest hospital
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL - SOMERSET
3.5 mi
3.5 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Young is a mixed practice specialist, with above-average Medicare volume (top 18% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Young experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Young performed 26,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Young receive payments from pharmaceutical companies?
Yes. Dr. Young received a total of $2,651 from 45 companies across 109 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Young's costs compare to other hematology & oncology specialists in Bridgewater?
Dr. Young's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Young) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Bridgewater
Browse hematology & oncology specialists in Bridgewater ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology